Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1966 4
1969 2
1974 2
1975 1
1976 1
1979 2
1980 2
1982 1
1983 4
1986 2
1987 3
1988 1
1989 3
1990 4
1991 2
1992 3
1993 5
1994 4
1995 8
1996 7
1997 5
1998 4
1999 9
2001 2
2002 1
2003 3
2004 1
2005 5
2006 2
2007 1
2008 2
2010 3
2011 5
2012 1
2013 5
2014 2
2015 4
2016 6
2017 4
2018 15
2019 5
2020 5
2021 1
2022 3
2023 0
Text availability
Article attribute
Article type
Publication date

Search Results

146 results
Results by year
Filters applied: . Clear all
Page 1
Use of an alternative method to evaluate erythema severity in a clinical trial: difference in vehicle response with evaluation of baseline and postdose photographs for effect of oxymetazoline cream 1·0% for persistent erythema of rosacea in a phase IV study.
Eichenfield LF, Del Rosso JQ, Tan JKL, Hebert AA, Webster GF, Harper J, Baldwin HE, Kircik LH, Stein-Gold L, Kaoukhov A, Alvandi N. Eichenfield LF, et al. Br J Dermatol. 2019 May;180(5):1050-1057. doi: 10.1111/bjd.17462. Epub 2019 Feb 27. Br J Dermatol. 2019. PMID: 30500065 Free PMC article. Clinical Trial.
BACKGROUND: Once-daily topical oxymetazoline cream 1.0% significantly reduced persistent facial erythema of rosacea in trials requiring live, static patient assessments. ...RESULTS: Among 835 patients (oxymetazoline n = 415, vehicle n = 420), significantly greater p …
BACKGROUND: Once-daily topical oxymetazoline cream 1.0% significantly reduced persistent facial erythema of rosacea in trials requiri …
A Randomized Controlled Pilot Study: Combined 595-nm Pulsed Dye Laser Treatment and Oxymetazoline Hydrochloride Topical Cream Superior to Oxymetazoline Hydrochloride Cream for Erythematotelangiectatic Rosacea.
Sodha P, Suggs A, Munavalli GS, Friedman PM. Sodha P, et al. Lasers Surg Med. 2021 Dec;53(10):1307-1315. doi: 10.1002/lsm.23439. Epub 2021 Jul 7. Lasers Surg Med. 2021. PMID: 34233378 Free PMC article. Clinical Trial.
BACKGROUND AND OBJECTIVES: We evaluated if oxymetazoline therapy combined with 595-nm pulsed dye laser (PDL) will be more beneficial than topical oxymetazoline alone for the improvement of erythematotelangiectatic rosacea. STUDY DESIGN/MATERIALS AND METHODS: This wa …
BACKGROUND AND OBJECTIVES: We evaluated if oxymetazoline therapy combined with 595-nm pulsed dye laser (PDL) will be more beneficial …
Hemodynamic and pharmacokinetic analysis of oxymetazoline use during nasal surgery in children.
Cartabuke RS, Anderson BJ, Elmaraghy C, Rice J, Tumin D, Tobias JD. Cartabuke RS, et al. Laryngoscope. 2019 Dec;129(12):2775-2781. doi: 10.1002/lary.27760. Epub 2019 Feb 20. Laryngoscope. 2019. PMID: 30786035 Free PMC article. Clinical Trial.
There are limited data on oxymetazoline pharmacokinetics in children who undergo general anesthesia. ...Mean arterial pressure did not increase with oxymetazoline instillation at the observed oxymetazoline serum concentrations (0.04-7.6 mug/L). ...
There are limited data on oxymetazoline pharmacokinetics in children who undergo general anesthesia. ...Mean arterial pressure did no …
Pivotal Trial of the Efficacy and Safety of Oxymetazoline Cream 1.0% for the Treatment of Persistent Facial Erythema Associated With Rosacea: Findings from the Second REVEAL Trial.
Baumann L, Goldberg DJ, Stein Gold L, Tanghetti EA, Lain E, Kaufman J, Weng E, Berk DR, Ahluwalia G. Baumann L, et al. J Drugs Dermatol. 2018 Mar 1;17(3):290-298. J Drugs Dermatol. 2018. PMID: 29537447 Clinical Trial.
The proportion of patients achieving the primary efficacy outcome was significantly greater with oxymetazoline versus vehicle (P=0.001). Similar results favoring oxymetazoline over vehicle were observed for the individual CEA and SSA scores (P less than 0.001 and P= …
The proportion of patients achieving the primary efficacy outcome was significantly greater with oxymetazoline versus vehicle (P=0.00 …
Pivotal Trial of the Efficacy and Safety of Oxymetazoline Cream 1.0% for the Treatment of Persistent Facial Erythema Associated With Rosacea: Findings from the First REVEAL Trial.
Kircik LH, DuBois J, Draelos ZD, Werschler P, Grande K, Cook-Bolden FE, Weng E, Berk DR, Ahluwalia G. Kircik LH, et al. J Drugs Dermatol. 2018 Jan 1;17(1):97-105. J Drugs Dermatol. 2018. PMID: 29320594 Clinical Trial.
The incidence of discontinuation due to TEAEs was low in both groups (oxymetazoline group, 1.8%; vehicle group, 0.5%). The most common TEAEs reported during the entire study period were application-site dermatitis, application-site erythema, and headache in the oxymetaz …
The incidence of discontinuation due to TEAEs was low in both groups (oxymetazoline group, 1.8%; vehicle group, 0.5%). The most commo …
A randomized controlled trial on the effects of oxymetazoline nasal spray after dacryocystorhinostomy among adult patients.
Sosuan GMN, Ranche FKT, Lagunzad JKD. Sosuan GMN, et al. BMC Res Notes. 2020 May 1;13(1):236. doi: 10.1186/s13104-020-05076-4. BMC Res Notes. 2020. PMID: 32357900 Free PMC article. Clinical Trial.
OBJECTIVES: The study aimed to determine the effect of oxymetazoline nasal spray on the patency of the fistula created after dacryocystorhinostomy, specifically: to compare the success of fistula formation with oxymetazoline versus placebo, and to compare the incide …
OBJECTIVES: The study aimed to determine the effect of oxymetazoline nasal spray on the patency of the fistula created after dacryocy …
Clinical Pharmacokinetics of Oxymetazoline Cream Following Topical Facial Administration for the Treatment of Erythema Associated With Rosacea.
Kuang AW, DuBois J, Attar M, Ahluwalia G. Kuang AW, et al. J Drugs Dermatol. 2018 Feb 1;17(2):213-220. J Drugs Dermatol. 2018. PMID: 29462230 Clinical Trial.
BACKGROUND: Oxymetazoline cream 1.0% is FDA-approved for the topical treatment of persistent facial erythema associated with rosacea in adults. ...Oxymetazoline, at all concentrations, was generally safe and well tolerated. ...
BACKGROUND: Oxymetazoline cream 1.0% is FDA-approved for the topical treatment of persistent facial erythema associated with rosacea …
Effects of common cold and concomitant administration of nasal decongestant on the pharmacokinetics and pharmacodynamics of nasal glucagon in otherwise healthy participants: A randomized clinical trial.
Guzman CB, Dulude H, Piché C, Rufiange M, Sadoune AA, Rampakakis E, Carballo D, Triest M, Zhang MX, Zhang S, Tafreshi M, Sicard E. Guzman CB, et al. Diabetes Obes Metab. 2018 Mar;20(3):646-653. doi: 10.1111/dom.13134. Epub 2017 Nov 19. Diabetes Obes Metab. 2018. PMID: 29053231 Free PMC article. Clinical Trial.
Cohort 2 participants (N = 18), who also had colds with nasal congestion, received a single dose of NG 2 hours after treatment with the decongestant oxymetazoline. Total symptoms score and other safety measures were assessed before and after NG administration. ...
Cohort 2 participants (N = 18), who also had colds with nasal congestion, received a single dose of NG 2 hours after treatment with the deco …
A comparative analysis of the decongestive effect of oxymetazoline and xylometazoline in healthy subjects.
Eskiizmir G, Hirçin Z, Ozyurt B, Unlü H. Eskiizmir G, et al. Eur J Clin Pharmacol. 2011 Jan;67(1):19-23. doi: 10.1007/s00228-010-0941-z. Epub 2010 Nov 11. Eur J Clin Pharmacol. 2011. PMID: 21069518 Clinical Trial.
BACKGROUND: Oxymetazoline and xylometazoline are locally effective and direct acting drugs that relieve nasal congestion. ...CONCLUSION: Oxymetazoline and xylometazoline are fast-acting and potent topical decongestants that have similar decongestive effects....
BACKGROUND: Oxymetazoline and xylometazoline are locally effective and direct acting drugs that relieve nasal congestion. ...CONCLUSI …
Fluticasone reverses oxymetazoline-induced tachyphylaxis of response and rebound congestion.
Vaidyanathan S, Williamson P, Clearie K, Khan F, Lipworth B. Vaidyanathan S, et al. Am J Respir Crit Care Med. 2010 Jul 1;182(1):19-24. doi: 10.1164/rccm.200911-1701OC. Epub 2010 Mar 4. Am J Respir Crit Care Med. 2010. PMID: 20203244 Clinical Trial.
RATIONALE: Chronic use of intranasal decongestants, such as oxymetazoline, leads to tachyphylaxis of response and rebound congestion, caused by alpha-adrenoceptor mediated down-regulation and desensitization of response. ...This effect was abolished on Day 14 (7.9 L x in(- …
RATIONALE: Chronic use of intranasal decongestants, such as oxymetazoline, leads to tachyphylaxis of response and rebound congestion, …
146 results